4//SEC Filing
Brandt Peter C. 4
Accession 0001415889-25-012286
CIK 0001740279other
Filed
May 6, 8:00 PM ET
Accepted
May 7, 8:45 PM ET
Size
21.6 KB
Accession
0001415889-25-012286
Insider Transaction Report
Form 4
IN8BIO, INC.INAB
Brandt Peter C.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-04-30$0.18/sh+81,967$15,115→ 681,538 total - Disposition to Issuer
Series B Warrants (right to buy)
2025-04-27−81,967→ 0 totalExercise: $1.50Exp: 2028-12-13→ Common Stock (81,967 underlying) - Award
Series B Warrants (right to buy)
2025-04-27+81,967→ 81,967 totalExercise: $0.18Exp: 2025-05-02→ Common Stock (81,967 underlying) - Disposition to Issuer
Series A Warrants (right to buy)
2025-04-27−81,967→ 0 totalExercise: $0.45Exp: 2025-10-04→ Common Stock (81,967 underlying) - Exercise/Conversion
Series A Warrants (right to buy)
2025-04-30−81,967→ 0 totalExercise: $0.18Exp: 2025-05-02→ Common Stock (81,967 underlying) - Exercise/Conversion
Common Stock
2025-04-30$0.18/sh+81,967$15,115→ 599,571 total - Award
Series A Warrants (right to buy)
2025-04-27+81,967→ 81,967 totalExercise: $0.18Exp: 2025-05-02→ Common Stock (81,967 underlying) - Exercise/Conversion
Series B Warrants (right to buy)
2025-04-30−81,967→ 0 totalExercise: $0.18Exp: 2025-05-02→ Common Stock (81,967 underlying)
Holdings
- 105,290(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]The securities are held by The Peter C. Brandt 2020-4 GRAT (the "GRAT"). The Reporting Person is the trustee of the GRAT and, as such, has voting and investment power over the shares held by the GRAT.
- [F2]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
- [F3]Fully vested and exercisable.
- [F4]The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.
- [F5]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 and expiration date of December 13, 2028. The exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
Documents
Issuer
IN8BIO, INC.
CIK 0001740279
Entity typeother
Related Parties
1- filerCIK 0001434099
Filing Metadata
- Form type
- 4
- Filed
- May 6, 8:00 PM ET
- Accepted
- May 7, 8:45 PM ET
- Size
- 21.6 KB